MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Syndax Pharmaceuticals Retained Earnings 2011-2026 | SNDX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Syndax Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.22 B | -902 M | -693 M | -544 M | -569 M | -495 M | -439 M | -366 M | -305 M | -260 M | -160 M | -136 M | -79.1 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -79.1 M | -1.22 B | -475 M |
Quarterly Retained Earnings Syndax Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.44 B | -1.38 B | -1.31 B | -1.22 B | -1.13 B | -1.04 B | -975 M | -902 M | -830 M | -779 M | -734 M | -693 M | -654 M | -618 M | -581 M | -544 M | -640 M | -619 M | -596 M | -569 M | -569 M | -569 M | -569 M | -495 M | -495 M | -495 M | -495 M | -439 M | -439 M | -439 M | -439 M | -366 M | -366 M | -366 M | -366 M | -305 M | -305 M | -305 M | -305 M | -260 M | -260 M | -260 M | -260 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -260 M | -1.44 B | -614 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Amgen
AMGN
|
-25.1 B | $ 350.12 | 2.98 % | $ 188 B | USA |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-535 M | $ 12.68 | 2.92 % | $ 3.97 B | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
-469 M | - | - | $ 8.42 M | USA |
 |
argenx SE
ARGX
|
-861 M | $ 781.8 | 2.14 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
-1.14 B | $ 24.48 | 5.18 % | $ 3.11 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
5.3 B | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.39 B | $ 1.5 | 9.93 % | $ 399 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.9 | 3.72 % | $ 9.38 B |  Australia |
 |
BioNTech SE
BNTX
|
-410 M | $ 91.86 | 2.5 % | $ 27.2 B | Germany |
 |
CymaBay Therapeutics
CBAY
|
-978 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.68 | 4.28 % | $ 16.8 M | USA |
 |
Avid Bioservices
CDMO
|
-572 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-611 M | - | - | $ 1.41 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Cabaletta Bio
CABA
|
-517 M | $ 3.05 | -0.65 % | $ 306 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 3.1 | 2.31 % | $ 6.75 B | Israel |
 |
Checkpoint Therapeutics
CKPT
|
-371 M | - | - | $ 169 M | USA |
 |
Cerus Corporation
CERS
|
-1.08 B | $ 1.92 | 4.08 % | $ 366 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-201 M | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
-349 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
-2.52 B | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-454 M | - | -4.36 % | $ 27 M | USA |
 |
Cellectar Biosciences
CLRB
|
-269 M | $ 2.81 | 2.18 % | $ 7.33 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-1.43 B | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-903 M | - | - | $ 2.02 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Cyclerion Therapeutics
CYCN
|
-267 M | $ 3.43 | -1.43 % | $ 8.64 M | USA |